AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
Essential Maintenance
: All Authorea-powered sites will be offline 9am-10am EDT Tuesday 28 May
and 11pm-1am EDT Tuesday 28-Wednesday 29 May. We apologise for any inconvenience.
Sachi Nakano
Public Documents
1
A case of unresectable combined hepatocellular and cholangiocarcinoma treated with at...
Naoto Saito
and 13 more
April 01, 2022
An 81-year-old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5-month progression-free survival. Atez/Bev might exhibit efficacy for CHC patients.